Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Short Interest Update

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 21,880,000 shares, a growth of 39.6% from the November 30th total of 15,670,000 shares. Based on an average daily trading volume, of 4,270,000 shares, the short-interest ratio is presently 5.1 days.

Hedge Funds Weigh In On Taysha Gene Therapies

Several large investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp bought a new stake in Taysha Gene Therapies in the 2nd quarter worth about $1,018,000. Principal Financial Group Inc. purchased a new stake in shares of Taysha Gene Therapies during the second quarter valued at approximately $48,000. Privium Fund Management B.V. bought a new stake in Taysha Gene Therapies during the second quarter worth $213,000. Rhumbline Advisers bought a new stake in Taysha Gene Therapies during the second quarter worth $413,000. Finally, The Manufacturers Life Insurance Company boosted its position in Taysha Gene Therapies by 109.0% in the second quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company's stock worth $298,000 after purchasing an additional 69,487 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Stock Down 5.9 %

Shares of TSHA stock traded down $0.11 during trading hours on Friday, reaching $1.75. The company had a trading volume of 1,600,983 shares, compared to its average volume of 2,845,679. The company has a market cap of $358.65 million, a price-to-earnings ratio of 2.78 and a beta of 0.79. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. Taysha Gene Therapies has a 12 month low of $1.19 and a 12 month high of $4.32. The business has a fifty day simple moving average of $2.12 and a 200-day simple moving average of $2.24.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Canaccord Genuity Group upped their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a "buy" rating in a report on Friday, November 15th. Chardan Capital reissued a "buy" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $6.63.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.